- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.07. | EMA CHMP recommends marketing authorisation for Moderna's RSV vaccine | ||
| 28.06. | FDA grants Fast Track designation to Tubulis' TUB-040 for ovarian cancer treatment | ||
| 27.06. | FDA approves Verona Pharma's Ohtuvayre for COPD treatment | ||
| 26.06. | Augustine raises €17m to advance lead candidate into trials for neuro conditions | ||
| 25.06. | Takeda's LIVTENCITY receives approval in Japan for CMV infections | ||
| 24.06. | Juniper Biologics to distribute Caris Life Sciences' molecular profiling services in MEA | ||
| 21.06. | Rosemont acquires Pharma-Data to enhance global product development | ||
| 20.06. | Yellowstone Biosciences launches to develop soluble bispecific cancer therapies | ||
| 19.06. | Iambic secures $50m to bolster clinical oncology programme pipeline | ||
| 18.06. | Pyros Pharmaceuticals receives FDA approval for infantile spasms drug | ||
| 17.06. | Takeda, Ascentage Pharma sign option agreement for olverembatinib | ||
| 14.06. | Quadram and SKAN partner for microbial therapies development | ||
| 13.06. | Sibylla Biotech, MD Anderson to develop cancer treatments | ||
| 12.06. | DoH expands research partnership with Penn Medicine | ||
| 11.06. | FDA grants fast track status for GC Biopharma and Novel Pharma's GC1130A | ||
| 10.06. | FDA accepts Eisai's sBLA for intravenous LEQEMBI to treat early Alzheimer's | ||
| 07.06. | PharmaCord to boost pharma services with Permira's investment | ||
| 06.06. | FDA grants orphan drug status to Agomab's AGMB-447 for IPF treatment | ||
| 05.06. | Repare Therapeutics secures FDA Fast Track designation for ovarian cancer therapy | ||
| 04.06. | Pfizer and Abu Dhabi partners to boost sickle cell disease research | ||
| 03.06. | Telix seeks BLA for TLX250-CDx aimed at kidney cancer imaging | ||
| 31.05. | Weave Bio secures $10m in seed funding round | ||
| 30.05. | ExpressionEdits secures $13m to develop protein-based therapies | ||
| 29.05. | Lucy Therapeutics secures $12.5m for neurological treatment development | ||
| 28.05. | RevolKa signs deal with Daiichi Sankyo for functional proteins |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
